The data demonstrated that amulirafusp alfa achieved profound B-cell depletion while exhibiting an excellent safety and tolerability profile, alongside robust and durable clinical efficacy.

This marks the fourth consecutive year that IMM2510 has been featured at ASCO, the premier global oncology conference, further validating the robust global R&D capabilities and sustained potential of this blockbuster bispecific therapy.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces First Patient Enrolled in Phase II Randomized Controlled Study of IMM0306 for the Treatment of Systemic Lupus Erythematosus

ImmuneOnco Secures IND Approval for amulirafusp alfa (IMM0306) in Primary Sjögren's Syndrome

A National Investigators' Meeting for the "Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study of IMM0306 for Injection (Amulirafusp Alfa) in Combination with Lenalidomide versus Placebo in Combination with Lenalidomide in Subjects with Relapsed/Refractory Follicular Lymphoma," sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco"), was successfully held in Harbin.